UB250
ProductCefazolin Sodium for Injection
Strength1.0g; 0.5g
IndicationsOtitis media; Bronchitis; Pneumonia; Respiratory tract infection; Urinary tract infection; Skin and soft tissue infection; Bone infection; Joint infection; Sepsis; Endocarditis infective; Hepatobiliary infection; Eye infection; Ear infection; Nasal infection; Throat infection; Surgical prophylaxis
TherapeuticsInfectious Diseases
GMPCN - NMPA; JP - PMDA
RegistrationJapan
ModalitiesSmall Molecule
Exclusive Summary
- - Off-patent globally with long market history and steady demand, enabling rapid multi-country distribution.
- - First-line perioperative prophylaxis in WHO and multi-society guidelines; 1.0 g/0.5 g are standard hospital doses.
- - ~310 million surgeries per year worldwide sustain large, recurring demand driven by SSI burden across care settings.
- - PMDA-GMP and Japan registration provide strong quality and compliance credentials for tenders in quality-sensitive markets.
- - Typically 60–90% cost savings vs originator; dual strengths reduce wastage and optimize total cost of care.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →